940 related articles for article (PubMed ID: 19426675)
1. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
[TBL] [Abstract][Full Text] [Related]
2. Splitomicin suppresses human platelet aggregation via inhibition of cyclic AMP phosphodiesterase and intracellular Ca++ release.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Thromb Res; 2009 Jun; 124(2):199-207. PubMed ID: 19327818
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
[TBL] [Abstract][Full Text] [Related]
4. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
[TBL] [Abstract][Full Text] [Related]
5. A noble function of BAY 11-7082: Inhibition of platelet aggregation mediated by an elevated cAMP-induced VASP, and decreased ERK2/JNK1 phosphorylations.
Lee HS; Kim SD; Lee WM; Endale M; Kamruzzaman SM; Oh WJ; Cho JY; Kim SK; Cho HJ; Park HJ; Rhee MH
Eur J Pharmacol; 2010 Feb; 627(1-3):85-91. PubMed ID: 19913011
[TBL] [Abstract][Full Text] [Related]
6. 2-Aminochromones block human platelet aggregation by inhibiting cyclic AMP-dependent phosphodiesterase leading to reduced platelet phospholipase C activity.
Benjamin CW; Lin AH; Morris J; Wishka DG; Gorman RR
J Pharmacol Exp Ther; 1993 Apr; 265(1):457-62. PubMed ID: 7682615
[TBL] [Abstract][Full Text] [Related]
7. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
8. Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation.
Nyby MD; Sasaki M; Ideguchi Y; Wynne HE; Hori MT; Berger ME; Golub MS; Brickman AS; Tuck ML
J Pharmacol Exp Ther; 1996 Aug; 278(2):503-9. PubMed ID: 8768697
[TBL] [Abstract][Full Text] [Related]
9. Dicentrine, a novel antiplatelet agent inhibiting thromboxane formation and increasing the cyclic AMP level of rabbit platelets.
Yu SM; Chen CC; Ko FN; Huang YL; Huang TF; Teng CM
Biochem Pharmacol; 1992 Jan; 43(2):323-9. PubMed ID: 1310852
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of platelet aggregation by olive oil phenols via cAMP-phosphodiesterase.
Dell'Agli M; Maschi O; Galli GV; Fagnani R; Dal Cero E; Caruso D; Bosisio E
Br J Nutr; 2008 May; 99(5):945-51. PubMed ID: 17927845
[TBL] [Abstract][Full Text] [Related]
11. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets.
Lam SC; Guccione MA; Packham MA; Mustard JF
Thromb Haemost; 1982 Apr; 47(2):90-5. PubMed ID: 6285543
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
Hoet B; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
[TBL] [Abstract][Full Text] [Related]
13. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
[TBL] [Abstract][Full Text] [Related]
14. Mode of action of 2-(diethylamino)-7-ethoxychromone on human platelets.
Leoncini G; Maresca M; Colao C; Buzzi E; Mazzei M
Cell Biochem Funct; 1991 Apr; 9(2):79-85. PubMed ID: 1718622
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
Manns JM; Brenna KJ; Colman RW; Sheth SB
Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of GBH on platelet aggregation through inhibition of intracellular Ca2+ mobilization in activated human platelets.
Park WH; Kim HK; Nam KS; Shon YH; Jeon BH; Moon SK; Kim MG; Kim CH
Life Sci; 2004 Nov; 75(25):3063-76. PubMed ID: 15474558
[TBL] [Abstract][Full Text] [Related]
17. Effects of DK-002, a synthesized (6aS,cis)-9,10-Dimethoxy-7,11b-dihydro-indeno[2,1-c]chromene-3,6a-diol, on platelet activity.
Lee KS; Khil LY; Chae SH; Kim D; Lee BH; Hwang GS; Moon CH; Chang TS; Moon CK
Life Sci; 2006 Feb; 78(10):1091-7. PubMed ID: 16153663
[TBL] [Abstract][Full Text] [Related]
18. Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition.
Brito FC; Kummerle AE; Lugnier C; Fraga CA; Barreiro EJ; Miranda AL
Eur J Pharmacol; 2010 Jul; 638(1-3):5-12. PubMed ID: 20412790
[TBL] [Abstract][Full Text] [Related]
19. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.
Lee JJ; Jin YR; Lim Y; Hong JT; Kim TJ; Chung JH; Yun YP
Vascul Pharmacol; 2006 Sep; 45(3):148-53. PubMed ID: 16916624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]